Alterity Therapeutics Limited - Depositary Receipt (Common Stock) (ATHE)
Summary
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
Alterity (ATHE) Up on Interim Data From Advance MSA Study
Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.
Alterity Therapeutics Limited - Depositary Receipt (Common Stock) Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YA Yinka Akinsola Blue Trust Inc. | 40 | $52.4 | $164.4 | $112 | 213.74% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 21 | $64.68 | $86.31 | $21.63 | 33.44% |
| WTM W. Travis McKinney HB Wealth Management LLC | 58,460 | $219,809.6 | $242,024.4 | $22,214.8 | 10.11% |
 Christopher C. Powers Farther Finance Advisors, LLC | 22 | $83 | $90.42 | $7.42 | 8.94% |
Alterity Therapeutics Limited - Depositary Receipt (Common Stock) (ATHE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alterity Therapeutics Limited - Depositary Receipt (Common Stock) ever had a stock split?
Alterity Therapeutics Limited - Depositary Receipt (Common Stock) Profile
| Biotechnology Industry | Healthcare Sector | David A. Stamler CEO | NASDAQ (CM) Exchange | 02155X106 CUSIP |
| AU Country | 10 Employees | - Last Dividend | 9 Jan 2023 Last Split | 5 Sep 2002 IPO Date |
Overview
Alterity Therapeutics Limited is a pioneering company focused on the development of novel therapeutics for the treatment of neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, Parkinson's disease, and other neurological disorders. The company, which has been operational since 1997, is located in Melbourne, Australia. Initially known as Prana Biotechnology Limited, it underwent a rebranding to Alterity Therapeutics Limited in April 2019. With its commitment to innovation in the field of neurological disorders, Alterity Therapeutics is at the forefront of research and development efforts to provide new treatment options for these challenging conditions.
Products and Services
- ATH434
ATH434 is Alterity Therapeutics' leading drug candidate currently in Phase I clinical trial, targeting the treatment of Parkinson's disease. This innovative therapeutic approach aims to offer a novel solution for managing and potentially altering the course of Parkinson's disease, shedding hope for those affected by this debilitating condition.
- ATH434-201
This derivative of ATH434 is in Phase II clinical trial, specifically designed to treat multiple system atrophy at an early stage. ATH434-201 represents a strategic expansion of the company's portfolio into addressing more specific neurodegenerative disorders within the spectrum of Parkinsonian syndromes.
- ATH434-202
Similar to ATH434-201 but focused on the advance stage of multiple system atrophy, ATH434-202 is also in Phase II clinical trial. This development underscores Alterity Therapeutics' dedication to providing treatments across different stages of neurodegenerative diseases, catering to a broader patient population.
- PBT2
Having completed a Phase 2a clinical trial, PBT2 addresses Alzheimer's disease, offering a potential treatment option for this profoundly impactful neurodegenerative condition. The completion of this trial stage marks a significant milestone in the quest for Alzheimer's disease therapies, indicating the company's ongoing commitment to groundbreaking research in neurological health.
